Transaminitis Recurrence Following Anti-TB Rechallenge in ESRD

Introduction to Rechallenge Protocols

The American Thoracic Society recommends a specific sequential reintroduction protocol that can distinguish between drugs and often allows successful rechallenge in patients with end-stage renal disease (ESRD) and prior drug-induced hepatotoxicity 2, 3

Pyrazinamide (PZA) has the highest recurrence risk of hepatotoxicity when it was the initial offending agent, with hepatotoxicity rates of approximately 1% even at standard doses during active TB treatment 1
PZA metabolites accumulate in renal insufficiency, increasing hepatotoxicity risk even at reduced frequencies 1, 3, 5
The Centers for Disease Control and Prevention (CDC) and the American Thoracic Society recommend careful monitoring and sequential reintroduction protocols to minimize the risk of recurrent hepatotoxicity 2, 3

Dosing intervals for PZA must be extended to three times weekly (not daily) at 25-35 mg/kg per dose in patients with creatinine clearance <30 mL/min or on hemodialysis 3, 5
Ethambutol also requires three times weekly dosing at 20-25 mg/kg per dose due to 80% renal clearance 3, 5
Isoniazid and rifampin can be given at standard doses (300 mg and 600 mg respectively) even in ESRD, as they are hepatically metabolized 3, 5

For patients with severe, unstable liver disease or confirmed PZA-induced hepatotoxicity, a 9-month regimen without PZA (isoniazid, rifampin, and ethambutol for 2 months, followed by 7 additional months of isoniazid and rifampin) is recommended 6
Regimens with minimal hepatotoxicity, such as combining ethambutol with a fluoroquinolone, cycloserine, and a second-line injectable, can be used for 18-24 months in severe cases 6

Intensive monitoring is mandatory during any rechallenge attempt in ESRD patients, including measurement of serum aminotransferases and total bilirubin every 1-4 weeks for the first 2-3 months 6
Therapeutic drug monitoring is recommended for all anti-TB drugs in ESRD patients to ensure adequate peak concentrations without excessive accumulation 5, 4
The American College of Clinical Pharmacy recommends against reducing doses in renal impairment, as this lowers peak concentrations and compromises concentration-dependent bacterial killing; instead, extend dosing intervals 3, 5